BiotechTube

Caspofungin + Amphotericin B Deoxycholate

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Candidiasis, Invasive

Conditions

Candidiasis, Invasive

Trial Timeline

Jan 15, 2014 → Feb 28, 2018

NCT ID
NCT01945281

About Caspofungin + Amphotericin B Deoxycholate

Caspofungin + Amphotericin B Deoxycholate is a phase 2 stage product being developed by Merck for Candidiasis, Invasive. The current trial status is terminated. This product is registered under clinical trial identifier NCT01945281. Target conditions include Candidiasis, Invasive.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01945281Phase 2Terminated

Competing Products

20 competing products in Candidiasis, Invasive

See all competitors
ProductCompanyStageHype Score
MicafunginAstellas PharmaPhase 1
33
Isavuconazole + Caspofungin + VoriconazoleAstellas PharmaPhase 3
77
Micafungin + fluconazoleAstellas PharmaPhase 3
77
Micafungin (Mycamine)Astellas PharmaPhase 1
33
Fluconazole + MicafunginAstellas PharmaApproved
85
Micafungin + CaspofunginAstellas PharmaPhase 3
77
Micafungin + FluconazoleAstellas PharmaPhase 3
77
MicafunginAstellas PharmaPhase 2
52
micafungin + caspofunginAstellas PharmaPhase 3
77
micafungin + amphotericin B deoxycholateAstellas PharmaPhase 3
77
FK463Astellas PharmaPhase 2
52
Micafungin + Liposomal Amphotericin BAstellas PharmaPhase 3
77
SHR8008 + FluconazoleJiangsu Hengrui MedicinePhase 3
77
SHR8008 capsule + Fluconazole capsuleJiangsu Hengrui MedicinePhase 3
77
L-743,872MerckPre-clinical
23
CaspofunginMerckPhase 2
52
L-743,872MerckPhase 2
52
Caspofungin acetate + PlaceboMerckPhase 2
52
Caspofungin + Normal SalineMerckApproved
85
caspofungin acetateMerckPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85